adMare BioInnovations,
Abdera is a precision oncology company developing novel next-generation targeted alpha therapies (TATs) for patients with relapsed, refractory and metastatic cancers. The seed financing of Abdera includes a total commitment of CAD
'The adMare team is proud to launch our third new well-funded company this fiscal year.
TATs are a potentially transformative new class of drugs based on therapeutic antibodies armed with high-energy radioisotopes that emit alpha particles to selectively destroy cancer tumor cells. Abdera's core technology comprises a proprietary and modular radioimmunoconjugate platform that is optimized to selectively deliver radioisotopes, including Actinium-225. Abdera will use its platform to enable the rapid development of a broad range of safe and efficacious therapies that will serve patients with limited treatment options.
'Our antibody discovery operating system provides a powerful vehicle for quick and efficient venture creation,' said
Abdera's founding management team is comprised of leading biopharmaceutical industry executives, including adMare Venture Partner Dr.
'In building Abdera, we identified the most promising early-stage technologies for this high-potential area of drug development together with a proven executive team,' said Dr.
About adMare BioInnovations
adMare BioInnovations is
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the
Contact:
Tel: +1(438) 998-2676
Email: afachini@admarebio.com
(C) 2021 Electronic News Publishing, source